FOLH1 and xerostomia: A consistent limitation of the current generation of 225Ac-PSMA therapeutic agents is the dose limiting xerostomia from salivary gland and lacrimal gland radiation exposure (Kratochwil et al. 2017; Taieb et al. 2018).